SCHEMBL2809932

SCHEMBL2809932

COc1ccc(CN2CCc3nn(Cc4ccccc4)c4nc(N5CCN(CC(=O)N6CCCC6)CC5)nc2c34)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
HTT P42858 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
CFTR P13569 1/20 0.41
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40
FAAH O00519 1/20 0.38
SIGMAR1 Q99720 2/20 0.37
CLPP Q16740 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
NTSR1 P30989 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13131680 0.89 ADORA3 (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL2811750 0.87 HTT (0.47) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL2808405 0.86 CFTR (0.49) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL2809473 0.84 TSHR (0.42) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL2814404 0.84 HRH4 (0.44) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL538222 0.82 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL2814817 0.81 KDM4E (0.42) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL2808261 0.81 TSHR (0.45) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL2813116 0.79 ALDH1A1 (0.47) ALDH1A1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL2809524 0.79 ADORA2A (0.40) ALDH1A1HTTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 ALDH1A1 924/4885HTT 2797/4885MEN1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.